MeSH term
Frequency | Condition_Probility | Alleles | 5 | 0.0 |
Alu Elements/*genetics | 2 | 6.0 |
English Abstract | 3 | 0.0 |
Gene Frequency | 6 | 0.0 |
Humans | 43 | 0.0 |
*Polymorphism, Genetic | 5 | 0.0 |
Russia | 2 | 2.0 |
Adult | 10 | 0.0 |
Case-Control Studies | 4 | 0.0 |
*Genetic Markers | 2 | 0.0 |
Genotype | 2 | 0.0 |
Male | 19 | 0.0 |
Middle Aged | 14 | 0.0 |
Polymorphism, Genetic | 4 | 0.0 |
Research Support, Non-U.S. Gov't | 23 | 0.0 |
Risk Factors | 5 | 0.0 |
Genetics, Population | 2 | 0.0 |
Child | 4 | 0.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Aged | 9 | 0.0 |
Female | 18 | 0.0 |
Prognosis | 2 | 0.0 |
Base Sequence | 11 | 0.0 |
Introns/genetics | 2 | 0.0 |
Molecular Sequence Data | 10 | 0.0 |
*Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 7 | 0.0 |
Tissue Plasminogen Activator/*genetics | 7 | 46.0 |
Comparative Study | 6 | 0.0 |
Factor VII/analysis | 2 | 6.0 |
*Hemostasis | 2 | 1.0 |
Prospective Studies | 4 | 0.0 |
Blood Proteins/analysis | 2 | 1.0 |
*Fibrinolysis | 4 | 3.0 |
Lipids/blood | 2 | 0.0 |
Breast Neoplasms/*genetics | 3 | 0.0 |
*Chromosomes, Human, Pair 8 | 12 | 5.0 |
*Gene Amplification | 2 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
Genetic Markers | 7 | 0.0 |
Linkage (Genetics) | 2 | 0.0 |
Lod Score | 3 | 0.0 |
Pedigree | 5 | 0.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Adolescent | 4 | 0.0 |
*Linkage (Genetics) | 2 | 0.0 |
Fibrin/*metabolism | 2 | 5.0 |
Blotting, Southern | 2 | 0.0 |
*Chromosome Deletion | 2 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Fibrinogen/metabolism | 2 | 0.0 |
DNA | 2 | 0.0 |
Polymerase Chain Reaction | 7 | 0.0 |
Animals | 3 | 0.0 |
Hybrid Cells | 2 | 0.0 |
*Chromosome Mapping | 4 | 0.0 |
Cell Line | 2 | 0.0 |
*Variation (Genetics) | 2 | 0.0 |
Chromosomes, Human, Pair 8 | 2 | 1.0 |
Crosses, Genetic | 2 | 0.0 |
Gonadorelin/*genetics | 2 | 25.0 |
